Skip to main content

Ligand Pharmaceuticals Incorporated

corporate_fare Company Profile

Ligand Pharmaceuticals Incorporated

LGND·NASDAQ·Life Sciences·CIK 0000886163

Ligand Pharmaceuticals Incorporated is a biopharmaceutical royalty company that acquires and creates diversified royalty streams from high-value medicines by deploying capital and licensing technologies. The company primarily invests in and structures royalty interests in mid- to late-stage development and commercial biopharmaceutical products to generate long-duration, non-dilutive cash flows with a lean corporate cost structure. Capital deployment and technology licensing drive long-term growth. Ligand partners capital through royalty purchases, development-stage financing arrangements, and acquisitions of companies or assets with embedded royalty rights to create cash-flowing royalties. In addition to royalty investment activities, Ligand operates two infrastructure-light, royalty-generating platform technologies: Captisol® and NITRICIL®. These technologies have existing royalty streams and potential for incremental royalties through partner-driven development and commercialization. Revenue is primarily generated from royalties on sales of products commercialized by partners, supplemented by Captisol material sales and contract revenue from license fees and milestone payments. Ligand partners with biopharmaceutical companies for late-stage development, regulatory execution, and commercialization, while focusing on capital deployment, portfolio construction, and risk management, leveraging partners' infrastructure to avoid high costs. Ligand is a biopharmaceutical royalty aggregator, focusing on disciplined capital allocation to differentiated late-stage assets and operating royalty-generating, infrastructure-light platform technologies. The company has 12 major commercial stage royalty assets, which comprise the majority of its royalty revenue. Ligand maintains a portfolio of more than 90 additional commercial and development-stage programs. In 2022, Ligand refined its strategy to focus on a more efficient, high margin, low infrastructure version of its historical model.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 32 items for LGND at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Ligand Pharmaceuticals Reports Strong Q1 2026 Results, Reaffirms Full-Year Guidance
  • Ligand Secures 47% Shareholder Support for XOMA Royalty Acquisition
  • Ligand Pharmaceuticals Terminates TR-Beta Program License with Viking Therapeutics Amidst Dispute
  • Ligand Pharmaceuticals Details XOMA Royalty Acquisition Impact, Raises 2026 Guidance
  • Ligand Pharmaceuticals to Acquire XOMA Royalty for $739M, Boosting Portfolio and Raising 2026 EPS Guidance

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$268.09M
Net Income
$124.45M
Diluted EPS
$6.13
Op. Cash Flow
$49.36M
Free Cash Flow
$48.91M
Operating Income
$41M
Cash & Equivalents
$174.93M
Total Debt
$446.19M
Debt / Equity
0.44×
Net Margin
46.4%
Shares Outstanding
19.77M sh
Source: 10-K · filed 2026-02-27 · accession 0000886163-26-000006

Recent Capital Actions

  • 2026-02-27 Proposed ATM Program $100M

    per share, offered pursuant to this prospectus and the accompanying prospectus. In accordance with the terms of the Sales Agreement, we may offer and sell shares of our common stock having an aggregate offering price of…

Detected from SEC filings (8-K, S-4, POS AM, 6-K). Last 12 months.
$286.85
52-week range · as of 2026-10-30 $175.89 – $326.63
Market cap
$5.74B
Volume
259.8K (1.2× avg)
3-mo avg 223.2K
Live data · 2026-11-22 12:54 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed LGND - Filings & News (Page 2)

LGND
May 07, 2026, 7:03 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $226.51
Real-time Price: $286.85 info
Change: +$60.34 (+27%) info
Market Cap: $5.738B info
LGND
May 01, 2026, 9:15 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
Price at Filing: $227.44
Real-time Price: $286.85 info
Change: +$59.41 (+26%) info
Market Cap: $5.738B info
LGND
Apr 30, 2026, 4:41 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $229.77
Real-time Price: $286.85 info
Change: +$57.08 (+25%) info
Market Cap: $5.738B info
LGND
Apr 27, 2026, 7:37 PM EDT
Filing Type: DEFA14A
Importance Score:
9
Price at Filing: $241.00
Real-time Price: $286.85 info
Change: +$45.85 (+19%) info
Market Cap: $5.738B info
LGND
Apr 27, 2026, 9:41 AM EDT
Filing Type: DEFA14A
Importance Score:
9
Price at Filing: $238.00
Real-time Price: $286.85 info
Change: +$48.85 (+21%) info
Market Cap: $5.738B info
LGND
Apr 27, 2026, 9:29 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $240.64
Real-time Price: $286.85 info
Change: +$46.21 (+19%) info
Market Cap: $5.738B info
LGND
Apr 27, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $238.00
Real-time Price: $286.85 info
Change: +$48.85 (+21%) info
Market Cap: $5.738B info
LGND
Apr 21, 2026, 4:02 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $226.67
Real-time Price: $286.85 info
Change: +$60.18 (+27%) info
Market Cap: $5.738B info
LGND
Mar 26, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $204.56
Real-time Price: $286.85 info
Change: +$82.29 (+40%) info
Market Cap: $5.738B info
LGND
Feb 27, 2026, 5:23 PM EST
Filing Type: S-3ASR
Importance Score:
7
Price at Filing: $198.31
Real-time Price: $286.85 info
Change: +$88.54 (+45%) info
Market Cap: $5.738B info
LGND
Feb 27, 2026, 4:02 PM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $198.31
Real-time Price: $286.85 info
Change: +$88.54 (+45%) info
Market Cap: $5.738B info
LGND
Feb 26, 2026, 7:05 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $191.50
Real-time Price: $286.85 info
Change: +$95.35 (+50%) info
Market Cap: $5.738B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets